Clinical trial
Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With…
NCT00268697 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00268697 |
|---|---|
| Title | Efficacy of Lapaquistat Acetate Alone and With Ezetimibe in Subjects With Primary Dyslipidemia. |
| Official title | A Double-Blind, Double-Dummy, Randomized, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Lapaquistat Acetate 100 mg and Lapaquistat Acetate 100 mg Administered in Combination With Ezetimibe 10 mg vs Ezetimibe 10 mg in Subjects With Primary Dyslipidemia |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypercholesterolemia |
| Intervention type | Drug |
| Interventions | Lapaquistat acetate, Lapaquistat acetate and ezetimibe, Ezetimibe |
| Enrollment | 1,267 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Jan 1, 2007 |
| First posted | Dec 22, 2005 |
| Last update posted | May 24, 2012 |
| Countries | Estonia, Latvia, Russia, Serbia |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: